cladribine has been researched along with Carcinoma, Renal Cell in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Q; Lu, M; Xiao, L; Xu, B | 1 |
| Nelson, JA; Pan, BF | 1 |
| Beutler, E; Carrera, CJ; Carson, DA; Copeland, B; Kawasaki, H; Kosty, M; Piro, LD; Saven, A; Waltz, T; Zyroff, J | 1 |
3 other study(ies) available for cladribine and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Identification of Novel Genes and Associated Drugs in Advanced Clear Cell Renal Cell Carcinoma by Bioinformatic Methods.
Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Cladribine; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Prognosis; Protein Serine-Threonine Kinases | 2022 |
Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cladribine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Kidney Neoplasms; Oxidoreductases; Transfection; Vidarabine | 2007 |
2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies.
Topics: Adult; Aged; Astrocytoma; Bone Marrow; Brain Neoplasms; Carcinoma, Renal Cell; Cladribine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasms; Nervous System | 1993 |